Opus Genetics (NASDAQ:IRD – Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.01, Zacks reports. The company had revenue of $3.87 million for the quarter, compared to the consensus estimate of $1.17 million. Opus Genetics had a negative return on equity of 59.72% and a negative net margin of 324.45%.
Opus Genetics Stock Performance
Shares of NASDAQ:IRD traded down $0.06 during trading on Wednesday, reaching $1.08. 204,290 shares of the stock were exchanged, compared to its average volume of 170,733. Opus Genetics has a 12 month low of $1.07 and a 12 month high of $3.40.
Analyst Ratings Changes
Separately, HC Wainwright initiated coverage on Opus Genetics in a research note on Wednesday. They issued a “buy” rating and a $8.00 price target on the stock.
About Opus Genetics
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.
Read More
- Five stocks we like better than Opus Genetics
- Best Stocks Under $5.00
- Rocket Lab is the Right Stock for the Right Time
- Differences Between Momentum Investing and Long Term Investing
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- What is the Euro STOXX 50 Index?
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for Opus Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opus Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
